Cardiology

Widaplik is a single pill combination of telmisartan, amlodipine and indapamide used to lower blood pressure in adult patients.

Investigators found that simvastatin added to escitalopram for patients with obesity and major depressive disorder did not have increased antidepressive effects.

The primary challenges include disruption in medication supply and increased demand for essential medications due to heightened health concerns.

Esaxerenone is a nonsteroidal mineralocorticoid receptor blocker that is being studied for its effectiveness for diabetes-associated mineralocorticoid receptor-related hypertension.

Researchers aimed to estimate the impact of using behavioral science principles within communication intended for hypertension medication adherence.

By protecting pregnant patients from cardiometabolic risk factors, healthier blood pressure can be promoted for children.

Acetaminophen exposure can increase the risk of perforation, ulceration, bleeding, heart failure, hypertension, and chronic kidney disease.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

Hypertension and obstructive sleep apnea are considered independent risk factors for cardiovascular diseases as well as diabetes.

The drug shows a decrease in proteinuria and is well tolerated and safe, including for Black patients with chronic kidney disease.

Technology, such as continuous glucose monitors, changes the way patients are treated, but more work needs to be done for racial, ethnic, and socioeconomic disparities.

Pharmacists can help manage complications from long COVID-19, as no medications can treat it.

Patients with pulmonary arterial hypertension (PAH) received the maximum tolerated dose of background therapy with sotatercept or the placebo to the therapy.

The decision makes the RNAi therapeutic the only therapy approved by the FDA to treat ATTR-CM and hATTR-PN.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, discuss medications and devices used for improving cardiovascular health among patients with or without diabetes.

The new approval is an oral suspension for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy.

Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.

Currently, there is a gap in treatment for this patient population and intracerebral hemorrhagic stroke is considered an orphan disease.

Crystal Zhou, PharmD, APh, AHSCP, BCACP, joined Drug Topics to further discuss the Cut Hypertension Program and nontraditional roles within health care.

The study authors report that long-term daily administration of amlodipine induced behavioral changes in the rats during their open field test.

A program that includes peer coaching and monitoring tools can help pharmacists better manage hypertension in patients.

Currently, blood-thinning medications are only prescribed to patients who have already had a heart attack or stroke, as the drugs can cause serious bleeding.

Cardiovascular health is known to be associated with the probability of having active or developing migraine in the future.

Crystal Zhou, PharmD, APh, AHSCP, BCACP, discussed her role as Lead Pharmacist of the Cut Hypertension Program.

Tryvio was given FDA approval on March 19, 2024.

Poor cardiometabolic health is associated with cognitive impairment in later life, but there is no clear association between cardiometabolic trajectories and early markers.

The prevalence of high blood pressure is highest in Mississippi at 40.2% compared with the lowest in Colorado at 24.6%.

Ozempic is now the most broadly indicated glucagon-like peptide-1 receptor agonist across the pharmaceutical drug market.